Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Sorafenib - induced thyroiditis in patient with a relapse of acute myelomonocytic leukemia with FLT3-ITD mutation].

Terapevticheskii arkhiv - 15 Aug 2019

Balzhanova Y B, Parovichnikova E N, Sokolov A N, Ryzhko V V, Samtsova M A, Gribanova E O

Abstract excerpt

Sorafenib has been used in acute myeloid leukemias with FLT3-ITD mutation improving the outcomes. However the high incidence of treatment - emergent adverse event may be associated with treatment using sorafenib with cytotoxic chemotherapy. We have reported a case of severe thyroiditis in patient with a relapse of acute myelomonocytic leukemia. В последние годы сорафениб используется для улучшения результатов...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Recurrence

Share to Sorafenib

Source

Identifiers

PMID: 32598759
DOI: 10.26442/00403660.2019.08.000381

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Sorafenib - induced thyroiditis in patient with a relapse of acute myelomonocytic leukemia with FLT3-ITD mutation].PMID 32598759Read ↗

Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia.Semantic proximity Read ↗

[Efficacy and safety of Sorafenib as monotherapy to FLT3-ITD positive acute myeloid leukemia].Semantic proximity Read ↗

[The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].Semantic proximity Read ↗

[Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report].Semantic proximity Read ↗

[Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].Semantic proximity Read ↗

[Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation].Semantic proximity Read ↗

Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.Semantic proximity Read ↗

[Sorafenib in combination with chemotherapy as first-line therapy for FLT3-ITD positive acute myeloid leukemia].Semantic proximity Read ↗

TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

[The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen].Semantic proximity Read ↗

Post-transplant sorafenib effectively prevents relapse in FLT3-mutated acute myeloid leukemia.Semantic proximity Read ↗

Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.